- Upadacitinib, sold
under the
brand name
Rinvoq, is a
medication used for the
treatment of
rheumatoid arthritis,
psoriatic arthritis,
atopic dermatitis...
- 1007/s40265-019-01131-y. PMID 31093950. S2CID 155093525. "AbbVie
Receives FDA
Approval of
Rinvoq (upadacitinib), an Oral JAK
Inhibitor For The
Treatment of
Moderate to Severe...
- Adbry),
abrocitinib (Cibinqo),
baricitinib (Olumiant) and
upadacitinib (
Rinvoq).
Among monoclonal antibodies,
dupilumab and
tralokinumab are
approved to...
- 2023 revenues),
Imbruvica to
treat cancer ($3.6 billion in 2023 revenues),
Rinvoq to
treat arthritis ($4 billion in 2023 revenues),
Venclexta to
treat leukemia...
- the market. The JAK1
inhibitors tofacitinib (Xeljanz) and
upadacitinib (
Rinvoq) are
approved for the use in
active psoriatic arthritis. The TYK2 inhibitor...
-
Machine Facts for
prescribers (Fakta för förskrivare).
Retrieved July 2011 "
Rinvoq: EPAR –
Public ****essment
report Archived 21 July 2020 at the
Wayback Machine"...
